Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients

• Published in: Journal of thrombosis and thrombolysis Vol. 38; no. 2; pp. 127 - 136
• Main Authors: Wagner, Henrik, Angiolillo, Dominick J., ten Berg, Jurrien M., Bergmeijer, Thomas O., Jakubowski, Joseph A., Small, David S., Moser, Brian A., Zhou, Chunmei, Brown, Patricia, James, Stefan, Winters, Kenneth J., Erlinge, David
• Format: Journal Article
• Language: English
• Published: Boston Springer US 2014; Springer Nature B.V
• Subjects: Adolescent; Adult; Aged; Blood Platelets - metabolism; Body Weight; Cardiac and Cardiovascular Systems; Cardiology; Cardiology and Cardiovascular Disease; Clinical Medicine; Clopidogrel; Female; Hematology; Humans; Kardiologi; Kardiologi och kardiovaskulära sjukdomar; Klinisk medicin; Male; Medical and Health Sciences; Medicin och hälsovetenskap; Medicine; Medicine & Public Health; Middle Aged; Pharmacodynamics; Pharmacokinetics; Platelet Aggregation - drug effects; Platelet Aggregation Inhibitors - administration & dosage; Platelet Aggregation Inhibitors - pharmacokinetics; Ticlopidine - administration & dosage; Ticlopidine - analogs & derivatives; Ticlopidine - pharmacokinetics; Clopidogrel; Pharmacodynamics; Pharmacokinetics; Body weight
• DOI: 10.1007/s11239-013-0987-8
• ISSN: 0929-5305; 1573-742X

Body weight is a predictor of clopidogrel response. However, no prospective studies have compared pharmacodynamic (PD) and pharmacokinetic (PK) data based on body weight. We compared PD and PK effects of clopidogrel 75 mg in low body weight (LBW, <60 kg) and higher body weight (HBW, ≥60 kg) patients with stable coronary artery disease. LBW (n = 34, 56.4 ± 3.7 kg) and HBW (n = 38, 84.7 ± 14.9 kg) aspirin-treated patients received clopidogrel 75 mg for 10–14 days. The area under the concentration–time curve of active metabolite (Clop-AM) calculated through the last quantifiable concentration up to 4 h postdose, AUC (0–tlast ), was calculated by noncompartmental methods. Light transmission aggregometry (LTA) (maximum platelet aggregation and inhibition of platelet aggregation to 20 μM adenosine diphosphate (ADP), and residual platelet aggregation to 5 μM ADP), VerifyNow ® P2Y12 reaction units (PRU), and vasodilator-associated stimulated phosphoprotein phosphorylation platelet reactivity index (VASP–PRI) were performed. Mean AUC (0–tlast ) was lower in HBW than LBW patients: 12.8 versus 17.9 ng h/mL. HBW patients had higher platelet reactivity as measured by LTA (all p  ≤ 0.01), PRU (207 ± 68 vs. 152 ± 57, p  < 0.001), and VASP–PRI (56 ± 18 vs. 39 ± 17, p  < 0.001). More HBW patients exhibited high on-treatment platelet reactivity (HPR) using PRU (35 vs. 9 %) and VASP–PRI (65 vs. 27 %). Body weight correlated with PRU and VASP–PRI (both p  < 0.001), and inversely with log transformed AUC (0–tlast ) ( p  < 0.001). In conclusion, HBW patients had lower levels of Clop-AM, and higher platelet reactivity and rates of HPR than LBW subjects, contributing to their suboptimal response to clopidogrel.